Skip to main content

Chapters

Transcript

Challenges in the Development of Novel Cardiovascular Therapies: New Target for Lowering LDL: PCSK-9 - Cardiology Grand Rounds

Chief Medical Officer of Amgen, Paul Eisenberg, MD, discusses the insights he has learned working on drug development, specifically the cardiovacscular drug that lowers LDL, PCSK-9.

Created by

Medical Professional Education Center

Presenters

Paul Eisenberg, MD

Paul Eisenberg, MD

Senior Vice President, Global Medical and Chief Medical Officer Amgen

Related Videos

Transcatheter Aortic Valve Replacement (TAVR): Overview

Transcatheter Aortic Valve Replacement (TAVR): Overview

Physicians at the Washington University and Barnes-Jewish Heart & Vascular Center have extensive experience and expertise evaluating and treating people who may need transcatheter aortic valve replacement (TAVR).

Revascularization Controversies in Simple and Complex Coronary Artery Disease

Revascularization Controversies in Simple and Complex Coronary Artery Disease

Coronary atherosclerosis is a diffuse vascular process and a life-long disease where optimal medical therapy is the foundation for all patients with CAD.

Precision Medicine at the Extremes of Heritability

Precision Medicine at the Extremes of Heritability

Rahul Deo, MD, PhD and Assistant Professor in the Division of Cardiology at UCSF discusses how a type of facial recognition-based strategy is possible for segmentation within an echocardiogram.

AngioVac Procedure: Treatment for Deep Venous Thrombosis

AngioVac Procedure: Treatment for Deep Venous Thrombosis

Dr. Mohamed A. Zayed discusses how the AngioVac device offers an alternative to existing therapies that treat venous thromboembolism.

Empowering our Youth: How Teaching CPR in Schools Creates a Generation of First-Responders (and Saves Lives!) – 2016 AHA Symposium, Part 7

Empowering our Youth: How Teaching CPR in Schools Creates a Generation of First-Responders (and Saves Lives!) – 2016 AHA Symposium, Part 7

Lindsay Davis, Miss Ohio 2011 and patient advocate for SCA, discusses the importance of making CPR mandatory in high school.

Treating VT like Cancer: Entirely Noninvasive Cardiac Mapping and Ablation – 2016 AHA Symposium, Part 6

Treating VT like Cancer: Entirely Noninvasive Cardiac Mapping and Ablation – 2016 AHA Symposium, Part 6

Dr. Phillip Cuculich and Dr. Clifford Grant Robinson discuss noninvasive cardiac mapping and ablation, including understanding the effects of radioablation, what is cardiac radiobiology and how and where to deliver energy.

Too Soon? Too Late? When to Refer for Catheter Ablation? – 2016 AHA Symposium, Part 5

Too Soon? Too Late? When to Refer for Catheter Ablation? – 2016 AHA Symposium, Part 5

Dr. Daniel Cooper discusses the importance of choosing the right patient at the right time for catheter ablation, minimizing ICD shocks and erring on the side of early referral to maximize the benefits for the patient.

Do the Genes Fit? When to Order Genetic Testing? – 2016 AHA Symposium, Part 4

Do the Genes Fit? When to Order Genetic Testing? – 2016 AHA Symposium, Part 4

Dr. Nathan Stitziel discusses when to order genetic testing, how the patient should be evaluated for genetic testing and the genetic causes of SCA.

When to Put on the Vest and When to Take it Off? Appropriate Use of Wearable Defibrillators – 2016 AHA Symposium, Part 1

When to Put on the Vest and When to Take it Off? Appropriate Use of Wearable Defibrillators – 2016 AHA Symposium, Part 1

Dr. Marye Gleva discusses when a patient should wear a cardioverter-defibrillator, the risk factors associated with not wearing one and how a WCD works.